2型糖尿病患者に対して，レパグリニド（R）あるいはミチグリニド（M）/ボグリボース（V）配合錠を追加投与した際の血糖変動をCGMにて比較検討した。入院中の2型糖尿病患者12例を対象に，既存治療継続（C），既存治療にR追加治療，M/V配合錠追加治療を2日間ごとにCGMでその血糖変動を観察した。24時間平均血糖はM/V配合錠で既存治療よりも有意に改善しており，血糖変動幅に関してもM/Vで改善傾向を認めた。また，食後血糖上昇曲線下面積（AUC）もM/V配合錠においてRに比し，有意に低下していた。M/V配合錠は，R単剤よりも食後血糖を有意に改善させ，血糖日内変動を平坦化させる可能性が考えられた。

   We compared changes in the blood glucose level after the additional administration of repaglinide (R) or combination mitiglinide (M)/voglibose (V) tablets to patients with type 2 diabetes. The subjects were 12 inpatients with type 2 diabetes. The continuation of conventional treatment (C), R therapy in addition to conventional treatment, and additional therapy with combination M/V tablets were performed every two days to examine changes in the blood glucose level. The mean 24-hour blood glucose level after additional therapy with combination M/V tablets was significantly lower than after conventional treatment, and the rate of glycemic variability was slightly lower after additional therapy with combination M/V tablets. Furthermore, the area under the curve (AUC) for a postprandial increase in the blood glucose level after additional therapy with combination M/V tablets was significantly smaller than after R therapy. Combination M/V tablets may significantly reduce the postprandial blood glucose level in comparison with R alone, reducing diurnal fluctuations.